We studied the impact of the recruitment of NKG2D by its ligands ULBP1 and ULBP2 on the triggering of biological responses by Vγ9Vδ2 T cells (cytokine production and release of cytolytic granules). After testing grading doses of ULBP proteins, we concluded that the concentration of 1 μg/mL of ULBP proteins would be used in all experiments of the study (Supporting Information data 1). In the presence of ULBP1 or ULBP2, Vγ9Vδ2 T cells produce IFN-γ (Fig. 1B, left panel), TNF-α

(Fig. 1B, middle panel), and release JNK inhibitor chemical structure cytolytic granules (Fig. 1B, right panel), which is not the case in the presence of UL16. The cytokine production and the release of lytic granules are impaired when cells are pre-incubated with a blocking anti-NKG2D mAb (M585) meaning that the interaction between ULBP1 and ULBP2 with NKG2D www.selleckchem.com/products/pci-32765.html leads to the biological responses of Vγ9Vδ2 T cells. In human NK cells, NKG2D-triggered biological responses are dependent on PI3K pathways 31. In order to know if PI3K pathways are also involved in the downstream NKG2D recruitment in Vγ9Vδ2 T cells, we analyzed both the effects of two PI3K pharmacological inhibitors (LY-294002 and wortmannin) and the phosphorylation state of PKB, a PI3K kinase substrate. PI3K inhibitor treatments were performed following the protocol already described in 24, 32. Both LY-294002 (Fig. 1B) and wortmannin (Supporting Information data 2) inhibit cytokine production

and the release of lytic granules. Moreover, PKB phosphorylation is observed after NKG2D recruitment by ULBP1 and ULBP2 (Supporting Information data 3). Altogether, these results indicate that the biological responses of Vγ9Vδ2 T cells directly triggered upon NKG2D activation are dependent on PI3K pathways. Moreover, the other mechanisms Idelalisib mouse underlying NKG2D stimulation in Vγ9Vδ2 T cells were further studied through the analysis

of the effects of the pharmacological inhibitors PD 98059 and SB 203580, two pharmalogical inhibitors of ERK-2 and p38 MAP kinases, respectively. Both PD 98059 and SB 203580 treatments inhibit cytokine production and the release of lytic granules triggered through NKG2D recruitment (Supporting Information data 2). This suggests that these two pathways are also recruited after NKG2D activation in Vγ9Vδ2 T cells. The above results suggest that NKG2D recruitment by its ligands is sufficient to trigger biological functions in Vγ9Vδ2 T cells, as it is the case for NK cells. Nevertheless, several reports indicated that NKG2D could also act as a costimulatory receptor for the TCR-dependent activation of human cytotoxic T cells 33. In this regard, we studied the impact of TCR/NKG2D costimulation on both cytokine production and lytic granule release by Vγ9Vδ2 T cells. As an optimal concentration of physiological phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate (HMB-PP) (0.5 nM) triggers strong biological responses (Fig.